---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-25-000032"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:45:28.926720+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics appoints Michael Tung as CFO; reinitiates Phase 3 T1D trial

## Summary
- Michael Tung appointed EVP and CFO effective May 19, 2025; base salary $450,000, target bonus 40%.
- Tung brings 20+ years finance experience; previously CFO at AdvanCell, VP at FibroGen.
- Company reinitiated screening in CATT1 Phase 3 trial for cadisegliatin, oral T1D adjunct to insulin.
- Employment agreement includes 45,000 stock option grant, 9-month severance, 9-month non-compete.
- No prior CFO departure disclosed; appointment comes at 'critical inflection point' per CEO.

## SEC filing metadata
- accession: 0001641489-25-000032
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000032/0001641489-25-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000032/vtvt-20250519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-25-000032
- JSON: https://secwatch.observer/filing/0001641489-25-000032.json
- Plain text: https://secwatch.observer/filing/0001641489-25-000032.txt

## Key facts
- Executive change
  Michael Tung was appointed as executive vice president and chief financial officer at vTv Therapeutics Inc..
  - Action: appointed
  - Role: executive vice president and chief financial officer
  source text: On May 19, 2025, vTv Therapeutics Inc. (the “Company”) announced that the Company has appointed Michael Tung as executive vice president and chief financial officer of the Company, effective as of May 19, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000032/0001641489-25-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.